Diligence memo · auto-generated · as of July 2, 2026
Vivace Therapeutics, Inc.
Vivace Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Vivace Therapeutics, Inc. operates in Biotechnology, based in San Mateo.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vivace Therapeutics, Inc. has raised $61M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $30M on 2020-12-11.
Most recent recorded round closed around 2025-02-28.
Valuation (modeled)modeled
Provath models Vivace Therapeutics, Inc. at approximately $94M (range $35M–$148M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.21× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era. Within the normal band (121% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 30 months.
Last raise 16 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 85% of Biotechnology peers (4293 compared).
Modeled value ranks above 58% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.